Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by S Branchoux
Prm112 - Incorporation of Anti-Cancer Drugs Adverse Events in Health Economic Opinions of the French National Authority for Health (Has)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Use of Budget Impact Analysis (Bia) in Economic Evaluations of Drugs and Medical Devices Submitted to the French National Authority for Health (Has)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Exploring Uncertainty in Economic Evaluation of Medicines: A Review of the First Manufacturers' Submissions to the French National Authority for Health (Has)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn355 - Utility in French Health-Economic Opinions: Key Learnings of a Retrospective Analysis in Oncology Drugs
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Methodological Analyses of Budget Impact Models Submitted to the Haute Autorité De Santé (HAS) (French National Authority for Health)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pmu59 - Are There Any Implicit Guidelines for Including Adverse Events in Cost-Effectiveness Models Intended for French Health Authorities? An Analysis of Efficiency Opinions
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Prm34 - French Efficiency Opinions of the Economic and Public Health Committee (Ceesp): Is There an Impact on the Market Access for Innovative Drugs?
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Current Status of Health Foods Including Their Interactions With Drugs and Adverse Events
Yakugaku Zasshi
Pharmacology
Pharmaceutical Science
Health Care Under French National Health Insurance
Health Affairs
Medicine
Health Policy
Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
